These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2444993)

  • 1. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
    Fitscha P; Tiso B; Sinzinger H
    Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD).
    Fitscha P; Tiso B; Krais T; Sinzinger H
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374.
    Yardumian DA; Mackie IJ; Bull H; Machin SJ
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():359-62. PubMed ID: 2408446
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
    Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
    Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
    Kaliman J; Fitscha P; Barth H; Sinzinger H
    Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421
    [No Abstract]   [Full Text] [Related]  

  • 6. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
    Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level.
    Sinzinger H; Steurer G; Fitscha P; Kraupp O
    Prog Clin Biol Res; 1987; 242():19-23. PubMed ID: 2444986
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
    Oberender H; Krais T; Schäfer M; Belcher G
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostacyclin in vascular pathology--therapeutic possibilities.
    Gryglewski RJ; Szczeklik A
    Ann Clin Res; 1984; 16(5-6):253-61. PubMed ID: 6398663
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of eicosanoids on compliance, cardiovascular performance, and coagulation during hemodialysis.
    Schultze G; Heitz J; Krais T; Neumayer HH; Wagner K; Molzahn M
    Biomed Biochim Acta; 1984; 43(8-9):S426-9. PubMed ID: 6083787
    [No Abstract]   [Full Text] [Related]  

  • 11. Temporary inhibition of platelet function with iloprost (ZK36374) preserves canine platelets during extracorporeal membrane oxygenation.
    Cottrell ED; Kappa JR; Stenach N; Fisher CA; Tuszynski GP; Switalska HI; Addonizio VP
    J Thorac Cardiovasc Surg; 1988 Oct; 96(4):535-41. PubMed ID: 2459560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
    Thiemermann C; Schrör K
    Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
    Pedvis LG; Wong T; Frojmovic MM
    Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris.
    Bugiardini R; Galvani M; Ferrini D; Gridelli C; Mari L; Puddu P; Lenzi S
    Am J Cardiol; 1986 Sep; 58(6):453-9. PubMed ID: 2428231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ticlopidine of platelet function in men with stable angina pectoris.
    Berglund U; von Schenck H; Wallentin L
    Thromb Haemost; 1985 Dec; 54(4):808-12. PubMed ID: 3911481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet aggregation induced by adenosine diphosphate, collagen and adrenaline in human platelet subpopulations].
    Nubile G; Di Gregorio M; Ridolfi D; D'Alonzo L; Izzi L
    Quad Sclavo Diagn; 1987 Sep; 23(3):331-40. PubMed ID: 3140287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia.
    Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA
    Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of calcium antagonists on platelet function and vascular prostacyclin production.
    Pirich C; Schmid P; Fitscha P; Wytek R; O'Grady J; Sinzinger H
    Blood Press Suppl; 1994; 1():75-80. PubMed ID: 8205307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.
    Sinzinger H; Virgolini I; O'Grady J
    Prog Clin Biol Res; 1989; 301():85-96. PubMed ID: 2477859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.